Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety

Documenti analoghi

• The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
  di: Zbigniew Siudak, et al.
  Pubblicazione: (2025)
• The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
  di: Yuxin Fan, et al.
  Pubblicazione: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)
• Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
  di: Hasan Fareed Siddiqui, et al.
  Pubblicazione: (2025)
• Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
  di: Flora Lambert, et al.
  Pubblicazione: (2025)